Effects of Nebivolol on Exercise Tolerance and Left Ventricular Systolic and Diastolic Function

• Status: Completed
• Trial end date: 2014-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The goal of this pilot study is to effectively treat hypertension in subjects with either known or newly diagnosed hypertension and concurrent evidence of diastolic dysfunction. Due to the unique properties of nebivolol, it is hypothesized that there will be improvements in left ventricular (LV) systolic and diastolic function manifesting as increase exercise capacity in this patient population with primarily LV diastolic dysfunction. The present study was performed to determine the effects of nebivolol on blood pressure, exercise tolerance and parameters of left ventricular systolic and diastolic function in a group of hypertensive patients with echocardiographic evidence diastolic dysfunction.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Mercy Research; St. John's Health System, Missouri
• Collaborator: Forest Laboratories
• Treatments: Nebivolol

Criteria

Inclusion Criteria:

• Diagnosis (new or established) hypertension, defined by serial measurements >/= 140/90

• Evidence of diastolic dysfunction on echocardiography measured by tissue Doppler

Exclusion Criteria:

• Severe bronchospastic disease/ reactive airway disease

• Inability to tolerate beta blocker therapy including: >1st degree atrioventricular (AV) block, symptomatic hypotension, symptomatic bradycardia,

• Subjects with physical limitations that would prevent them from participating in an exercise treadmill test

• Age <18 or >90 years

• Those with life expectancy <1 year

• Subjects with class III/IV New York Heart Association (NYHA) heart failure symptoms

• Chronic Kidney Disease 3 or greater (CrCl <30 cc/min)

• Subjects with active ischemia or evidence of ischemia on initial stress echocardiography